54741_Image_jpeg.jpg
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 06, 2022 08:00 ET | Daxor Corporation
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...
54741_Image_jpeg.jpg
DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19
January 05, 2022 08:00 ET | Daxor Corporation
Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...
54741_Image_jpeg.jpg
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
January 04, 2022 08:00 ET | Daxor Corporation
Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
54741_Image_jpeg.jpg
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
November 16, 2021 08:00 ET | Daxor Corporation
Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021 ...
54741_Image_jpeg.jpg
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care
November 09, 2021 08:00 ET | Daxor Corporation
Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...
54741_Image_jpeg.jpg
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
September 14, 2021 08:30 ET | Daxor Corporation
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 07, 2021 08:30 ET | Daxor Corporation
Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer...
54741_Image_jpeg.jpg
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
September 01, 2021 08:30 ET | Daxor Corporation
Oak Ridge, TN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter to...
54741_Image_jpeg.jpg
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021
August 30, 2021 08:30 ET | Daxor Corporation
Company forecasts further increase in sales driven by new distributor agreements Oak Ridge, TN, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS
July 22, 2021 08:30 ET | Daxor Corporation
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government...